Lu Wang, MD, PhD
2 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer (NCT05757336) | Lu Wang, MD, PhD | 2022-12-22 |
| HAIC Combined With Toripalimab and Donafenib for Advanced BTC (NCT05350943) | Lu Wang, MD, PhD | 2022-03-01 |
Track Lu Wang, MD, PhD automatically
Every clearance here is in the API, with alerts when new ones post.